drugset / Trial / NCT07241936
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study adopts a multi-center, open-label, non-randomized trial design. It plans to enroll patients with Advanced solid tumor. Dose-escalation and PK-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with Different ADCs (DP303c/SYS6043/SYS6002/SYS6010) in this patient population, and to confirm the recommended phase 2 dose (RP2D).
Timeline
- Start
- 2025-11-13
- Primary completion
- 2027-10-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYS6002 | Other / unclassified | — | Intravenous |
| Subject | SYS6010 | Monoclonal antibody | — | Intravenous |
| Subject | SYS6043 | Other / unclassified | — | Intravenous |
| Subject | Sirolimus | Small molecule | — | Intravenous |
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | — | Intravenous |